We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 9 januari 2018

The Lancet: [News] Many FDA-approved cancer drugs might lack clinical benefit

[News] Many FDA-approved cancer drugs might lack clinical benefit
New research shows that less than half of the randomised controlled trials (RCTs) that support the approval of anticancer drugs by the US Food and Drug Administration (FDA) reach the threshold for clinical benefit as defined by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Read more

[News] Improved progression-free survival in metastatic breast cancer
Addition of lapatinib to trastuzumab plus an aromatase inhibitor significantly improves progression-free survival (PFS) in patients with metastatic breast cancer, according to new research.
Read more

[News] Smoking cessation medications ineffective in US smokers
New research shows that pharmacotherapies for quitting smoking are ineffective in promoting long-term smoking cessation among US smokers.
Read more

[Articles] Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
The addition of abiraterone acetate plus prednisone to ADT in patients with newly diagnosed, high-risk metastatic castration-naive prostate cancer improved overall PROs by consistently showing a clinical benefit in the progression of pain, prostate cancer symptoms, fatigue, functional decline, and overall HRQOL.
Read more

[Articles] Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
The combination of palbociclib, fulvestrant, trastuzumab, and pertuzumab had a significant effect on the expression of Ki67 at 2 weeks and at surgery. Triple targeting of ER, HER2, and RB1 in HER2-positive and ER-positive breast cancer could be an effective chemotherapy-free treatment strategy. Further clinical testing and additional molecular characterisation is necessary, not only in hormone receptor-positive tumours but also in tumours without HER2 amplification.
Read more